about
Coenzyme q10 therapyPharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease.Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrid models of the diseaseAMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome.Clinical applications of coenzyme Q10.Emerging roles of apoptotic microtubules during the execution phase of apoptosis.Targeting autophagy and mitophagy for mitochondrial diseases treatment.AMPK As A Target in Rare Diseases.The Connections Among Autophagy, Inflammasome and Mitochondria.Apoptotic cells subjected to cold/warming exposure disorganize apoptotic microtubule network and undergo secondary necrosis.AMPK Regulation of Cell Growth, Apoptosis, Autophagy, and Bioenergetics.Recovery of MERRF fibroblasts and cybrids pathophysiology by coenzyme Q10.Amitriptyline induces mitophagy that precedes apoptosis in human HepG2 cells.Stabilization Of Apoptotic Cells: Generation Of Zombie Cells.Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients.Critical role of AMP-activated protein kinase in the balance between mitophagy and mitochondrial biogenesis in MELAS disease.Metformin and caloric restriction induce an AMPK-dependent restoration of mitochondrial dysfunction in fibroblasts from Fibromyalgia patients.Enhancing folic acid metabolism suppresses defects associated with loss of Drosophila mitofusinSecondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblastsForcing contacts between mitochondria and the endoplasmic reticulum extends lifespan in a Drosophila model of Alzheimer's disease
P50
Q33956936-723906FF-5A95-448D-A0F8-FFE92BD8F3A8Q35686212-715D55EF-F4D6-4B99-8B45-57C77DC2420DQ36419316-5979D4B4-07AC-4194-921E-3B010D746EE0Q36549279-0F8070E8-64A2-4FD1-B73E-8761054858A5Q38175736-BFA4F5E6-033A-42D1-BA37-AE954D5F6267Q38588842-708A3F3F-F2DB-4D51-9F74-F34721EE1446Q38622293-C8717E68-2F63-43FD-8A4E-4983D96B97E4Q38693880-12A2AB6B-2517-40E8-8DEA-6DA027049566Q38845693-2A515CF8-7362-438B-8EF9-7710B23BF94BQ38975044-745AEAAB-4DF8-42A6-9033-3633B2ED1D07Q38998395-302F7BD2-3F23-411A-8280-1F4CCB71B431Q39392555-A21E45DA-A23B-485A-93F0-24A90FE86291Q41426376-A03C4A55-784E-4294-B893-66C08EF6FEF2Q46693248-19F52793-2A1E-4581-8433-3AA4160450A7Q48799106-AC86EB41-44F6-4082-B9C6-9DFAC4CA28C0Q50437571-BCCCD7DE-CC35-413B-9525-9D6DB8B41CE3Q50449918-9E5BA4A8-E256-4965-B2E5-8E3095F06A9AQ64054527-D8E7A821-6391-4C4E-8353-29FEB87B0BC4Q84062030-47C1CEF4-8490-4874-855B-0E683AF3F216Q91852580-0D7F3105-EE7F-40E9-B9F3-F700F69B0BE4
P50
description
researcher ORCID ID = 0000-0003-4534-4109
@en
wetenschapper
@nl
name
Juan Garrido-Maraver
@ast
Juan Garrido-Maraver
@en
Juan Garrido-Maraver
@es
Juan Garrido-Maraver
@nl
type
label
Juan Garrido-Maraver
@ast
Juan Garrido-Maraver
@en
Juan Garrido-Maraver
@es
Juan Garrido-Maraver
@nl
prefLabel
Juan Garrido-Maraver
@ast
Juan Garrido-Maraver
@en
Juan Garrido-Maraver
@es
Juan Garrido-Maraver
@nl
P108
P1153
26026590800
P21
P31
P496
0000-0003-4534-4109